{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:40:16Z","timestamp":1777470016667,"version":"3.51.4"},"reference-count":20,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"DOI":"10.1210\/jc.2009-0340","type":"journal-article","created":{"date-parts":[[2009,4,6]],"date-time":"2009-04-06T13:37:55Z","timestamp":1239025075000},"page":"1089-1091","source":"Crossref","is-referenced-by-count":20,"title":["Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome?"],"prefix":"10.1210","volume":"94","author":[{"given":"Christos S.","family":"Mantzoros","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113350026200_R1","first-page":"48","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults.","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113350026200_R2","first-page":"1961","article-title":"Clinical review 159: human immunodeficiency virus\/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies.","volume":"88","author":"Leow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113350026200_R3","first-page":"329","article-title":"Premature atherosclerosis in HIV-infected individuals\u2014focus on protease inhibitor therapy.","volume":"15","author":"Depairon","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041113350026200_R4","first-page":"795","article-title":"Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin.","volume":"36","author":"Nagy","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041113350026200_R5","first-page":"627","article-title":"Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy.","volume":"88","author":"Addy","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113350026200_R6","first-page":"941","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019041113350026200_R7","first-page":"1345","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041113350026200_R8","first-page":"1994","article-title":"Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.","volume":"54","author":"Javor","year":"2005","journal-title":"Diabetes"},{"key":"key\n\t\t\t\t2019041113350026200_R9","first-page":"570","article-title":"Leptin-replacement therapy for lipodystrophy.","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113350026200_R10","first-page":"142","volume":"41","author":"Andreev","journal-title":"Horm Metab Res"},{"key":"key\n\t\t\t\t2019041113350026200_R11","first-page":"532","article-title":"Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.","volume":"92","author":"Ebihara","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113350026200_R12","first-page":"753","article-title":"Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.","volume":"41","author":"Javor","year":"2005","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019041113350026200_R13","first-page":"1137","article-title":"The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with HIV-associated lipoatrophy and hypoleptinemia.","volume":"94","author":"Mulligan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113350026200_R14","first-page":"2605","article-title":"Recombinant methinoyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.","volume":"91","author":"Lee","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113350026200_R15","first-page":"991S","article-title":"Leptin in humans: lessons from translational research","volume":"89","author":"Bluher","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"key\n\t\t\t\t2019041113350026200_R16","first-page":"509","article-title":"Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.","volume":"300","author":"Lo","year":"2008","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113350026200_R17","first-page":"239","article-title":"Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients.","volume":"35","author":"Kotler","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041113350026200_R18","first-page":"2359","volume":"357","author":"Falutz","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113350026200_R19","first-page":"173","article-title":"r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans.","volume":"160","author":"Brennan","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113350026200_R20","first-page":"745","article-title":"Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 \u00d7 2 factorial, randomized, double-blinded, placebo-controlled trial.","volume":"40","author":"Gavrila","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/4\/1089\/10806534\/jcem1089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T23:32:28Z","timestamp":1555025548000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/4\/1089\/2596221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2009-0340","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,1]]}}}